Sign Up to like & get
recommendations!
0
Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_120
Abstract: rubicin, epirubicin, vinblastine, etoposide, paclitaxel, and topotecan. RTI‐79's PK characteristics are similar to rifabutin and exhibited no overt toxicity in mice at high doses. RTI‐79 did not exacerbate the known cardiotoxicity associated with doxorubicin as…
read more here.
Keywords:
rti;
ezh2 hdac;
dual inhibition;
ezh2 ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Stem Cell Reports"
DOI: 10.1016/j.stemcr.2018.11.013
Abstract: (Stem Cell Reports 9, 752–761; September 12, 2017) In Figure S2A of our originally published Supplemental Information, the image labeled as the ALP staining of H9-vehicle (control) hESCs was incorrectly chosen. We imaged two similar…
read more here.
Keywords:
ezh2 promotes;
stem cell;
inhibition ezh2;
cell ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.1813006116
Abstract: Significance The key epigenetic regulator EZH2 plays a central role in fibrosis and abnormal angiogenesis in scleroderma. EZH2-target genes mediating profibrotic and antiangiogenic effects in scleroderma patients have been identified and characterized. Inhibiting EZH2 by…
read more here.
Keywords:
fibrosis;
ssc;
ezh2;
angiogenesis scleroderma ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2018030262
Abstract: Microenvironmental stimuli affect EZH2 expression and function in CLL. Combined B-cell signaling and EZH2 inhibition showed synergistic effects on primary CLL cells.
read more here.
Keywords:
exerts synergistic;
ezh2 immune;
inhibition;
immune signaling ... See more keywords